Mourey F, Sureja V, Kheni D, et al. - Researchers conducted this multicenter, randomized, double-blind, placebo-controlled trial to test the safety and effectiveness of Saccharomyces cerevisiae variant boulardii CNCM I-3799 (S. boulardii CNCM I-3799) in the management of acute diarrhea in children. In total, 100 infants and children aged 3 to 36 months with acute diarrhea received medical care according to the World Health Organization guidelines on the management of acute diarrhea in children and were allocated randomly to the probiotic group (S. boulardii CNCM I-3799 at a daily dose of 5 billion CFU twice daily) or to the placebo group. Findings suggested an association of the administration of S. boulardii CNCM I-3799 with beneficial effects on the duration and severity of diarrhea. In children with acute diarrhea, S. boulardii CNCM I-3799 supplementation was shown to be effective in reducing the duration and severity of diarrhea in infants and children.